Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy

Table 7 Clinical symptom score (mean ± SD)

Group	Hepatic pain		Fatigue		Abdominal distension
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
TACE group (n = 119)	2.31 ± 0.56	2.07 ± 0.63	2.67 ± 0.87	2.35 ± 0.54	2.93 ± 0.62	2.37 ± 0.55
TACE + TARE group (n = 99)	2.29 ± 0.58	1.56 ± 0.72	2.54 ± 0.58	1.45 ± 0.63	2.79 ± 0.58	1.26 ± 0.66
χ2	0.258	5.576	0.720	11.357	1.709	13.545
P value	0.796	< 0.05	0.205	< 0.001	0.089	< 0.001

TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.